{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-027752","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2026-06-08T21:00:43+00:00","discovered_at":"2026-06-08T21:02:00.369681+00:00","generated_at":"2026-06-08T21:02:45.071848+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CFO Alan Weichselbaum departs; Andriy Mushak appointed fractional CFO at $6K/month","bullets":["Alan Weichselbaum departs as CFO effective June 6, 2026; no disagreement cited.","Andriy Mushak, CPA, appointed fractional CFO effective June 6, 2026; will serve as independent contractor.","Mushak will receive $6,000 per month under a one-year consulting agreement with LMAM Consulting Group.","Mushak has 20+ years accounting experience; previously at Baker Tilly US, LLP and co-founded LMAM in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-027752","json":"https://secwatch.observer/filing/0001493152-26-027752.json","markdown":"https://secwatch.observer/filing/0001493152-26-027752.md","text":"https://secwatch.observer/filing/0001493152-26-027752.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226027752/0001493152-26-027752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226027752/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:02:45.071848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d9db2493b","claim":"Andriy Mushak was appointed as fractional Chief Financial Officer at Telomir Pharmaceuticals, Inc..","evidence_excerpt":"On June 3, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company’s fractional Chief Financial Officer, effective as of June 6, 2026","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226027752/0001493152-26-027752-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"fractional Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"6cef5fb9a1","claim":"Alan Weichselbaum departed as Chief Financial Officer at Telomir Pharmaceuticals, Inc..","evidence_excerpt":"Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Telomir Pharmaceuticals, Inc. (the \"Company\"). Mr. Weichselbaum’s departure was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226027752/0001493152-26-027752-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will be no longer serving"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}